Tirzepatide vs. Semaglutide: Which One Actually Works Better?

The Core Difference

Both are GLP-1 receptor agonists, but they work differently:

• Semaglutide (Ozempic, Wegovy) activates one receptor: the GLP-1 receptor
• Tirzepatide (Mounjaro, Zepbound) activates two receptors: GLP-1 + GIP (glucose-dependent insulinotropic polypeptide)

The dual mechanism is why tirzepatide consistently shows greater weight loss in clinical trials — but that doesn’t automatically make it the right choice for everyone.

What the Clinical Data Actually Shows

Semaglutide (Wegovy 2.4mg/week)

From the STEP 1 trial (N=1,961, 68 weeks):

• Mean weight loss: 14.9% of body weight vs. 2.4% placebo
• 32% of participants lost 20% or more of body weight
• Source: Wilding JPH et al. NEJM 2021; PMID: 33567185

Tirzepatide (Zepbound 15mg/week)

From the SURMOUNT-1 trial (N=2,539, 72 weeks):

• Mean weight loss: 20.9% of body weight at 15mg dose vs. 3.1% placebo
• 57% of participants lost 20% or more of body weight
• Source: Jastreboff AM et al. NEJM 2022; DOI: 10.1056/NEJMoa2206038

Head-to-Head: SURMOUNT-5 Trial (2025)

The first direct comparison trial showed tirzepatide produced ~47% greater weight loss than semaglutide over 72 weeks in adults with obesity without diabetes (20.2% vs. 13.7% mean weight loss). This is the most rigorous comparison available.

Side Effect Comparison

Side Effect	Semaglutide	Tirzepatide
Nausea	~44%	~33%
Vomiting	~24%	~16%
Constipation	~24%	~33%
Diarrhea	~30%	~23%

Tirzepatide appears to have somewhat less nausea and vomiting but more constipation than semaglutide. Both are generally well-tolerated by most patients after the adjustment period.

Cost Comparison (2026)

Medication	Retail (no insurance)	Notes
Wegovy (semaglutide 2.4mg)	~$1,300/mo	Novo Nordisk savings programs available
Zepbound (tirzepatide 15mg)	~$1,050/mo	Eli Lilly savings card may apply

Zepbound is currently less expensive than Wegovy at retail. Telehealth platforms offering compounded versions of both may offer significantly lower prices, though the regulatory landscape for compounded tirzepatide is evolving rapidly.

How to Choose

Consider semaglutide if:

• You have more experience with it (more long-term data exists)
• Constipation is a major concern for you (somewhat more common with tirzepatide)
• Your prescriber has more clinical experience with semaglutide
• Cost is a major factor and Wegovy savings programs make it more accessible in your situation

Consider tirzepatide if:

• Maximum weight loss is your priority and the SURMOUNT data is compelling to you
• You have type 2 diabetes (Mounjaro has very strong cardiometabolic data)
• Nausea was a significant problem on semaglutide and you want to try an option with potentially less nausea
• Retail price is more favorable with Zepbound in your situation

Either option requires a prescription and physician oversight. The best drug is the one you can access, tolerate, and stay on consistently.

Can You Switch Between Them?

Yes, patients do switch between semaglutide and tirzepatide. There is no required washout period, but dose adjustments are necessary when switching. This decision should always be made with your prescribing physician.

Medical Disclaimer: This article is for informational purposes only. Drug selection should be made in consultation with a qualified healthcare provider based on your individual medical history and circumstances.